Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures
NCT ID: NCT00771927
Last Updated: 2014-10-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1005 participants
OBSERVATIONAL
2008-10-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
NCT01921205
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
NCT00655486
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
NCT00552305
Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
NCT00522275
Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors
NCT02276053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lacosamide
Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with add-on Vimpat
Lacosamide
Vimpat was used as per site routine practices, and in-line with the marketing authorization.
Other AED
Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with other approved AED as add-on therapy
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lacosamide
Vimpat was used as per site routine practices, and in-line with the marketing authorization.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are prescribed Vimpat or any other add-on Antiepileptic Drug (AED) may be included in the study
* The initiation of an add-on AED therapy can not be more than 2 days before the patient's start of the study
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bron, , France
Dijon, , France
La Tronche, , France
Montpellier, , France
Nantes, , France
Paris, , France
Saint-Brieuc, , France
Tain-l'Hermitage, , France
Aschaffenburg, , Germany
Bad Berka, , Germany
Berlin, , Germany
Bernau, , Germany
Bielefeld, , Germany
Bonn, , Germany
Dresden, , Germany
Düsseldorf, , Germany
Erlangen, , Germany
Essen, , Germany
Freiburg im Breisgau, , Germany
Göttingen, , Germany
Halle, , Germany
Hamburg, , Germany
Jena, , Germany
Kehl-Kork, , Germany
Kiel, , Germany
Koningstein-Falkenstein, , Germany
Krefeld, , Germany
Mainz, , Germany
Marburg, , Germany
München, , Germany
Münster, , Germany
Neuburg am Inn, , Germany
Neukirchen-Vluyn, , Germany
Oldenburg, , Germany
Osnabrück, , Germany
Potsdam, , Germany
Radeberg, Sachsen, , Germany
Ravensburg, , Germany
Rotenburg (Wümme), , Germany
Stuttgart, , Germany
Ulm, , Germany
Vogtareuth, , Germany
Westerstede, , Germany
Blaricum, , Netherlands
Heeze, , Netherlands
Nijmegen, , Netherlands
Barcelona, , Spain
El Vendrell, , Spain
Plymouth, Devon, United Kingdom
Fulwood, Preston, Lancashire, United Kingdom
Bangor, , United Kingdom
Birmingham, , United Kingdom
Cardiff, , United Kingdom
Dundee, , United Kingdom
Edinburgh, , United Kingdom
Leeds, , United Kingdom
Leicester, , United Kingdom
London, , United Kingdom
Middlesbrough, , United Kingdom
Salford, , United Kingdom
Sheffield, , United Kingdom
Stoke-on-Trent, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Product information
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP0942
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.